Welcome to
NUS Life Sciences Venturing Forum (NLSVF)

HARNESSING INNOVATION & NEW TECHNOLOGIES
-The NUS-BioSingapore Life Sciences Technology Showcase 2006 

Organised by:

Sponsored by:

About The Event:

The NUS BioSingapore Life Sciences Technology Showcase 2006 will incorporate the inaugural NUS Life Sciences Venturing Forum by NUS Enterpreneurship Centre.

In partnership with BioSingapore, the NUS Life Sciences Venturing Forum is industry-focused and is designed to feature:

• Emerging life sciences startups and spin-offs from universities and research institutes as well as private sectors
  


• Latest investment areas in life sciences industry
  


• Next-generation technologies in life sciences Industry based on technology scans
  


• Technology/company showcase

The 26 Jan event will provide a platform for companies looking for investments, business development, strategic partnership and marketing opportunities.

It will feature keynote speaker in the form of Mr. Steven Fang, Chairman of BioSingapore and Group CEO for Cordlife, Cytomatrix and Cell Sciences.

There will also be a panel of VCs and senior industry executives present to give feedbacks to life sciences start-up companies in terms of their market potential, business model, future possibilities in the life sciences industry.

Programme:

About The Keynote Speaker :

Mr. Steven Fang

Mr Steven Fang is Group CEO of CyGenics, a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies.  From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

In addition to holding an office with BioSingapore as Chairman, Mr Fang is currently also the President of Spirit of Entreprise (a non-profit organisation to recognise and promote entrepreneurship), Board Member of ACE /IAC of IE Singapore for Globalisation and Board member of the Singapore British Business Council.  Mr Fang is intimately familiar with the healthcare provider business, with over 15 years of sales and business development experience in the Asia Pacific region. He has previously worked for Sterling Withthrop, Baxter and Becton Dickinson, having undertaken business development assignments in Malaysia , Korea, Taiwan, and the Philippines, including the set up of private dialysis centres. While at Becton Dickinson, he was the General Manager for Singapore, Malaysia and Vietnam. More recently, Steven was the Director for Quality Healthcare Asia Ltd. Steven has a first degree in Computer Engineering, and completed his MBA with the University of Hull (UK) in business strategy.

Industry Panelists:

• Mr. Steven Fang (Group CEO of CyGenics Ltd)
  

• Dr Tan Sze Wee (CEO and MD of Rockeby biomed Ltd)
  
  
• Dr Michael Schroter (MD of Lilly Biology Systems Pte Ltd)
  
  
• Dr Paul Chapman (Director and Head, NGI CEDD Cognition & Neurodegeneration Centre, Singapore), GlaxoSmithkline
  
  
• Mr. Roland Yap (Executive Director, BioSingapore)



• Dr. Jui Lim (Director Investments, Bio*One Capital)

About the Presenting Companies:

Acacia Biomedical was started to exploit its patented platform technology in fully biodegradable drug eluting stent which has applications in coronary / peripheral vascular / ureteric / pulmonary stenting applications. The work is fully supported by one of the largest research group in NTU. The comparative advantage is its multi layered self expanding stent, which is not only fully biodegradable but capable of releasing drugs with extensive flexibility in the drug release profiles. This makes its technology at least a generation ahead of the recently commercialized Drug Eluting Stents.

BioMers is a venture engaged in developing polymer composite products for biomedical applications. By exploiting BioMers' patent pending technologies in the fabrication of fibre reinforced polymer composites, translucent orthodontic braces have been developed to meet the unfulfilled market demand for braces that are not clearly visible to others and have the necessary mechanical properties to straighten teeth effectively. With a superior product, BioMers targets the 1 million orthodontic patients in the U.S. who are currently seeking an aesthetic treatment for their crooked teeth. BioMers' products have generated interest from the two leading companies in the orthodontic industry and has recently been approached for possible partnerships.

BioMers seeks investment to complete product development, obtain regulatory approval and begin manufacturing of the products.

Bright Hermes (http://www.handenet.com/)

Bright Hermes is the Singapore-based sales & marketing operation representing China's Yunnan Hande Bio-Tech Co. Ltd. Yunnan Hande Bio-Tech Co. Ltd. has devoted to develop and manufacture paclitaxel API since its establishment in 1993. Today, Hande is the only Chinese company to have submitted US, European Drug Master Files for the production of paclitaxel API and Hande is one of a handful of cGMP producers of paclitaxel API and the only Chinese company to have obtained approval for its paclitaxel production from the US FDA and Chinese SFDA.

Bright Hermes is looking for marketing & sales as well as partnership/alliance opportunities with big pharmas to sell into the region using Singapore as its regional head office. It is also looking to raise funds for its initial business operations, and builds up its supply chain for the sourcing of raw materials for its production & manufacturing operations in China.

ElectroActiv Inc. has just been formed to exploit its patented platform technology developed and supported by a major research group in NTU. The technology uses novel PZT enabled actuators and micro pumps for use as a temporary blood pump implant to treat stage III CHF cases, to drive local drug releases, as a proximal device for removal of vascular atheroembolic debris / cholesterol, throumbus, lipids, and as a high frequency actuator device for ocular cataract removal. Its comparative technological advantage is its use of a impedance type mechanism to move fluids which can do without any forms of membranes, impellers, valves, to provide fully laminar and non impeded flow. The company is actively seeking funding at seed stage presently.

Lynk Biotechnologies is an innovative biotech company with competence in drug discovery and non-invasive drug delivery. Spunoff from the National University of Singapore in Year 2000, the Lynk Group (Lynk Biotechnologies and her subsidiary, MediLynk Pte Ltd) currently comprises 18 team members, working on multidisciplinary projects. Armed with diversified capabilities and creativity, Lynk has successfully created and commercialized several effective biomedical products. These include: MediLynkTM Transdermal Glucosamine Cream ad SportsLynk Pain & Itch Relieving Cream. More products have been lined up for official launch in year 2006m using in house labels such as CosmeLynkTM & PharmLynkTM. Lynk also holds key patents to technologies in drug discovery and the synthesis of biosurfacetants. These are being exploited in Lynk’s mid to long term programs.

Pro-Therapeutics Pte Ltd is the nation's first drug development company that leverages on technology derived from animal toxins. The company was formed around a strong portfolio of intellectual property licensed from Exploit Technologies, NUS and Virginia Commonwealth University. We have managed to obtain highly prized peptides with unique medical indications from a bank of rare animal toxins. These naturally occurring long proteins are then engineered using the Company's proprietary technology to generate small peptides that can be absorbed orally. The Company has contracted with Aptuit in Scotland and Guys Hospital/Quintiles in London to conduct the pre-clinical and Phase I clinical trials of its first product, a small orally available analgesic peptide. This pain medication derived from the King Cobra snake promises to be a very exciting and novel pain medication that has been engineered to show no toxic side effects. The first application in man will occur in 2006. The Company has also established collaborations with The Johns Hopkins University in the USA to develop anticoagulant medication.

Registration Information :

This event is open to all BioSingapore members, the National University of Singapore and members of the public. 

For registration, please click here

For other enquires about the event, please contact Mr Hong Hay at Tel:6516 5538 or email necv4@nus.edu.sg